Agilent Technologies Diagnostics and Genomics — Total Assets increased by 26.5% to $5.04B in Q3 2024 compared to the prior quarter. Year-over-year, this metric grew by 27.2%, from $3.97B to $5.04B. Over 3 years (FY 2021 to FY 2024), Diagnostics and Genomics — Total Assets shows an upward trend with a 11.0% CAGR.
An increase indicates expansion of the asset base, which should ideally be accompanied by proportional growth in revenue and operating income.
This represents the sum of all current and non-current assets controlled by the diagnostics and genomics segment, includ...
Standard balance sheet metric used to evaluate the scale and capital requirements of a business segment.
a_segment_diagnostics_and_genomics_total_assets| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.26B | $3.28B | $3.32B | $3.33B | $3.38B | $3.45B | $3.49B | $3.52B | $3.55B | $3.26B | $3.97B | $3.96B | $3.98B | $3.99B | $5.04B |
| QoQ Change | — | +0.5% | +1.3% | +0.2% | +1.8% | +1.8% | +1.3% | +0.9% | +0.8% | -8.3% | +21.8% | -0.1% | +0.4% | +0.2% | +26.5% |
| YoY Change | — | — | — | — | +3.7% | +5.1% | +5.1% | +5.9% | +4.9% | -5.5% | +13.7% | +12.6% | +12.1% | +22.5% | +27.2% |